Industrial clusters in biotechnology: Driving forces, development processes, and management practices

Industrial Clusters in Biotechnology: Driving Forces, Development Processes, and Management Practices

Volumn , Issue , 2004, Pages 1-225

  Chiesa, Vittorio ^a,b   Chiaroni, Davide ^a  

^a POLITECNICO DI MILANO   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84995470118     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/P360     Document Type: Book

References (98)

1. Adelberger K.E. (1999) “A Developmental German State? Explaining Growth in German Biotechnology andVenture Capital”, BRIEWorking Paper, n. 134.
2. Adler A.A., Conklin D. (2001) “Bioinformatics”, Encyclopedia of Life Sciences, Macmillan Publishers Ltd., Nature Publishing Group, London, UK.
3. Adler D.A. (2001) “Human genetics: online resources”, Encyclopedia of Life Sciences, Macmillan Publishers Ltd., Nature Publishing Group, London, UK.
4. Adomeit A., Baur A., Salfeld R. (2001) “A new model for disease management”, The McKinsey Quarterly, n. 4.
5. Alberghina L. (2001) “Genomica, Postgenomica e Biotecnologie di fronte alla complessità biologica”, Keiron, n. 7, 64-75.
6. Alberghina L., Cernia E. (1996) “Biotecnologie e Bioindustria”, UTET, Torino, Italy.
7. Allansdottir A., Bonaccorsi A., Gambardella A., Mariani M., Orsenigo L., Pammolli F., Riccaboni M. (2002) “Innovation and competitiveness in European biotechnology”, Enterprise Papers, n. 7.
8. AltAssets (2002) “Delivering on discovery: Private Equity investing in Biotechnology”.
9. Altshuler J., Flanagan A., Steiner M., Tollman P. (2001) “A revolution in R&D-How genomics and genetics are transforming the biopharmaceutical industry”, The Boston Consulting Group.
10. Audretsch D.B., Stephan P.E. (1996) “Company-scientist locational links: the case of biotechnology”, The American Economic Review, vol. 86, n. 3, 641-652.
11. Audretsch D.B., Stephan P.E. (2001) “Biotechnology in Europe: lessons from the USA”, International Journal of Biotechnology, vol. 3, n. 1/2, 168-183.
12. Augen J. (2002) “The evolving role of information technology in the drug discovery process”, DDT Drug Discovery today, vol. 7, n. 5, 315-323.
13. Baba Y. (2000) “Development of novel biomedicine based on genome science”, European Journal of Pharmaceutical Sciences, vol. 13, n. 1, 3-4.
14. Bastianelli E., Eckhardt J., Teirlynck O. (2001) “Pharma: can the middle hold?”, The McKinsey Quarterly, n. 1.
15. Becker M. (2001) “The Biotechnology Revolution”, BackOnBiotech.
16. Bergman E., Von Hertog P. (2001) “In pursuit of innovative clusters. Main findings from the OECD cluster focus group”, NIS Conference on “Networkand Cluster-oriented policies”, Vienna, Austria, 15-16 October.
17. Bergman E., Feser E., Sweeny S. (1996) “Targeting North Carolina Manufacturing: Understanding the State’s Economy through Industrial Cluster Analysis”, vol. I, Chapel Hill, North Carolina, US.
18. Bhandari M., Garg R., Glassman R. et al. (1999) “A genetic revolution in health care”, The McKinsey Quarterly, n. 4.
19. Biotechnology Industry Organisation (2001) “Guide to Biotechnology”.
20. Biotechnology Industry Organisation (2002) “Guide to Biotechnology”.
21. Boschma R. (2001) “Proximity and innovation”, Third Congress on “Proximity New Growth and Territories”, Paris, France, 13-14 December.
22. Boston Consulting Group (2001) “Assessment of Biotech clusters by the BCG”.
23. Breschi S., Lissoni F., Orsenigo L. (2001) “Success and failure in the development of biotechnology clusters: the case of Lombardy”, in Fuchs G., “Comparing the Development of Biotechnology Clusters”, Harwood Academic Publishers, Chur, Switzerland.
24. Brown S. (2001) “Achieving compliance for biologics”, Trends in Biotechnology, vol. 19, n. 8.
25. Bud R. (2001) “History of biotechnology”, Encyclopedia of Life Sciences, Macmillan Publisher Ltd., Nature Publishing Group, London, UK.
26. Buffinger N., Mascarenhas D.M. (2001) “Patenting genes and their products”, Encyclopedia of Life Sciences, Macmillan Publisher Ltd., Nature Publishing Group, London, UK.
27. Burrill&Company (2000) “Biotech 2000. Life Sciences Changes and Challenges”.
28. Burrill&Company (2001) “Biotech 2001. Life sciences: Genomics Proteomics … and more”.
29. Burrill&Company (2002) “Biotech 2002. Life sciences: Systems Biology”.
30. Burrill&Company (2003) “Biotech 2003. Life sciences: Revaulation and Restructuring …”.
31. Carroll M.L., Nguyen S.V., Batzer M.A. (2002) “Genome databases”, Encyclopedia of Life Sciences, Macmillan Publisher Ltd., Nature Publishing Group, London, UK.
32. Chiaroni D., Chiesa V., Toletti G. (2003) “The biotech revolution in Big Pharma Organization”, IEEE-IEMC Conference, Albany, US, 2-4 November.
33. Chiesa V. (2003) “La bioindustria-Strategie Competitive e Organizzazione Industriale nel Settore delle Biotecnologie Farmaceutiche”, ETAS, Milano, Italy.
34. Chiesa V. (2001) “R&D Strategy and organisation - Managing technical change in dynamic contexts”, Imperial College Press, London, UK.
35. Chiesa V., Toletti G. (2004) “How biotechnology changes pharma R&D: a managerial perspective”, International Journal of Biotechnology, vol. 5, n. 2, 125-140.
36. Chiesa V., Toletti G. (1999) “Network of alliances for innovation: the case of biotechnology”, Strategic Management Society 19th Annual International Conference in Berlin, Berlin, Germany, 3-6 October.
37. Cook J.D., Miller F.W., Ruiz-Funes J.P.M. (1997) “Food Biotechnology”, The McKinsey Quarterly, n. 3.
38. Cooke P. (1994) “The Associational Economy - Firms, Regions, and Innovation”, Oxford University Press, Oxford, UK.
39. Cooke P. (1999) “Regional Innovation systems: general findings and some new evidence from biotechnology clusters”, Nects-Rictes Conference “Regional Innovation System in Europe”, Donostia, Spain, 29 September- 2 October.
40. Cooke P. (2001) “Regional innovation and learning systems, clusters and local and global value chains”, Kiel Institute International Workshop on Innovation Clusters and Interregional Competition, Kiel, Germany, 12-13 November.
41. Cooke P. (2001) “Clusters as key determinants of economic growth: the example of biotechnology”, in Mariussen A. (editor), “Cluster Policies - Cluster Development? A contribution to the analysis of the new learning economy”, Nordregio, Stockholm, Norway.
42. Cookson C. (2002) “Still no end to the slowdown”, Financial Times, 29 April.
43. Coriat B., Weinstein O. (2002) “Organizations, firms and institutions in the generation of innovation”, Research Policy, vol. 31, 273-290.
44. Dear P.H. (2001) “Genome Mapping”, Encyclopedia of Life Sciences, Macmillan Publisher Ltd., Nature Publishing Group, London, UK.
45. DiMasi J.A. (2001) “Tufts Center for the Study of Drug Development Pegs Cost of a New Prescription Medicine at $802 million”, Tufts University.
46. Edmunds III R.C., Ma P.C., Tanio C.P. (2001) “Splicing a cost squeeze into the genomics revolution”, The McKinsey Quarterly, n. 2.
47. Enright M. (1998) “Regional clusters and firm strategy”, in Chandler A.D., Hagstrom P., and Solvell O., “The Dynamic Firm - The Role of Technology, Strategy, Organization, and Regions”, Oxford University Press, Oxford, UK.
48. Enright M. (2001) “Regional clusters: what we know and what we should know”, Kiel Institute International Workshop on Innovation Clusters and Interregional Competition, Kiel, Germany, 12-13 November.
49. Ernst&Young (1999) “Biotech ’99: Bringing the Gap Ernst&Young’s 13-th Biotechnology Industry Annual Report”.
50. Ernst&Young (2000) “Convergence. The Biotechnology Industry Report”.
51. Ernst&Young (2000) “Evolution. Ernst&Young’s Seventh Annual European Life Sciences Report”.
52. Ernst&Young (2001) “Back to Basics. Ernst&Young’s 6-monthly Update of the European Life Sciences Industry H1 2001”.
53. Ernst&Young (2001) “Australian Biotechnology Report”.
54. Ernst&Young (2001) “Integration. Ernst&Young’s Eighth Annual European Life Sciences Report 2001”.
55. Ernst&Young (2001) “Millennium in Motion. Global Trends Shaping the Health Sciences Industry”.
56. Ernst&Young (2002) “TheYear in Review (Europe)”.
57. Ernst&Young (2003) “Endurance. The Biotechnology Industry Report”.
58. European Commission (1998) “Directive 99/44 EC of the European Parliament and of the Council”, Official Journal of the European Communities.
59. European Federation of Pharmaceutical Industries and Associations (EFPIA), (2003) “Efpia Infigures 2002”.
60. Flattmann G.J., Kaplan J.M. (2001) “Patenting expressed sequence tags and single nucleotide polymorphisms”, Nature Biotechnology, vol. 19, n. 7, 683-684.
61. Garner J.L., Nam J., Ottoo R.E. (2000) “Determinants of corporate growth opportunities of emerging firms”, Journal of Economics and Business, vol. 54, 73-93.
62. George G., Zahra S.A., Wheatley K.K., Khan R. (2001) “The effects of alliance portfolio characteristics and absorptive capacity on performance. A study of biotechnology firms”, The Journal of High Technology Management Research, vol. 12, 205-226.
63. Giescke S. (1999)“Moving goose ahead: catch up strategies of the German system of innovation. The case of biotechnology”, European Meeting on Applied Evolutionary Economics, Grenoble, France, 7-9 June.
64. Gilsing V.A., Roelandt T.J.A., Van Sinderen J. (2000) “New policies for the New Economy cluster-based innovation policy: international experiences”, Annual EUNIP Conference, Tilburg, Netherlands, 7-9 December.
65. Goldman Sachs (2001) “Healthcare: Biotechnology. Europe”, Goldman Sachs global equity research.
66. Guardia M.J. (2002) “Modelling and control in bioprocesses”, Trends in Biotechnology, vol. 20.
67. Hung L.W., Kim S.H. (2001) “Genome, proteome, and the quest for a full structure-function description of an organism”, Encyclopedia of Life Sciences, Macmillan Publisher Ltd., Nature Publishing Group, London, UK.
68. IBM Business Consulting Services (2003) “Pharma 2005: Marketing to the Individual”.
69. IBM Business Consulting Services (2003) “Pharma 2010: The Threshold of Innovation”.
70. Institute of Professional Representatives before the European Patent Office (2001) “An Introduction to Patents in Europe”.
71. Jacobs D., DeMan A.P. (1996) “Clusters, Industrial Policy and Firm Strategy: a Menu Approach”, Technology Analysis and Strategic Management, vol. 8, n. 4, 425-437.
72. Jain V., Mitchell J.J., Ross P. (2002) “Financing in a down market”, Biotechnology Investors’ ForumWorldwide, vol. 2.
73. Kluge J., Meffert J., Stein L. (2000) “The German road to innovation”, The McKinsey Quarterly, n. 2.
74. La Montagne J.R. (2001) “Biotechnology and research: promise and problems”, The Lancet, vol. 358, n. 9294, 1723-1724.
75. Lemariè S., Mangematin V., Torre A. (2000) “Is the creation and development of biotech SMEs localized? Conclusions drawn from the French case”, Small Business Economics, vol. 17, n. 1/2, 61-76.
76. Lindgren T. (2000) “Sweden: Strong and Growing”, Cap Gemini Ernst & Young.
77. Lord Sainsbury, Minister for Science (1999) “Biotechnology Clusters”, UK Counsel.
78. Love J. (2000) “How much does it cost to develop a new drug”, Geneva Meeting of the MSE Working Group on R&D, Geneva, Switzerland, 2 April.
79. Mallik A., Pinkus G.S., Sheffer S. (2002) “Biopharma’s capacity crunch”, The McKinsey Quarterly, Special Edition: Risk and resilience.
80. McCain L. (2002) “Informing technology policy decisions: the US Human Genome Project’s ethical, legal and social implications programs as a critical case”, Technology in Society, vol. 24, n. 1/2, 111-132.
81. McCutchen Jr W.W., Swamidass P.M. (2001) “Effect of R&D expenditures and funding strategies on the market value of biotech firm”, Journal of Engineering and Technology Management, vol. 12, 287-299.
82. Mytelka L., Farinelli F. (2000) “Local Clusters, Innovation Systems and Sustained Competitiveness”, United Nations University, Institute for New Technologies, Discussion Paper, vol. 5.
83. Paisner G. (2001) “Europe’s biotech VCs are waiting out the downturn by making larger investments”, Red Herring, December.
84. Pharmaceutical Research and Manufacturers of America (PhRMA) (2001) “Pharmaceutical Industry Profile 2001”.
85. Pharmaceutical Research and Manufacturers of America (PhRMA) (2002) “Pharmaceutical Industry Profile 2002”.
86. Porter M. (1990) “The Competitive Advantage of Nations”, Mcmillian Publisher Ltd., Nature Publishing Group, London, UK.
87. Porter M. (1998) “The Adam Smith address: location, clusters, and the “new” microeconomics of competition”, Business Economics, vol. 23, n. 1.
88. PriceWaterhouseCoopers (1998) “Pharma 2005. An Industrial Revolution in R&D”.
89. PriceWaterhouseCoopers (1999) “Pharma 2005. Silicon Rally: The race to e-R&D”.
90. PriceWaterhouseCoopers (2000) “Global Pharmaceutical Company Partnering Capabilities Survey”.
91. PriceWaterhouseCoopers (2000) “Global Pharmaceuticals Sector Insights. Analysis and Opinions on Merger and Acquisition Activity”.
92. Rosenfeld Stuart A. (1996) “Overachievers, Business Clusters that Work: Prospects for Regional Development”, Regional Technology Strategies, Chapel Hill, North Carolina, US.
93. Rosenfeld Stuart A. (1997) “Bringing Business Clusters into the Mainstream of Economic Development”, European Planning Studies, vol. 5, n. 1, 1-23.
94. Sauter T. (2002) “New trends in applied microbiology”, Trends in Biotechnology, vol. 20, n. 1, 43-44.
95. Signals Magazine (2003) “The Big Spin (Off)”.
96. Swain B.J. (1998) “Biotechnology patents in the pharmaceutical industry”, Financial Times, Healthcare Management Reports.
97. Swann G.M.P., Prevezer M., Stout D. (1998) “The Dynamics of Industrial Clustering”, Oxford University Press, Oxford, UK.
98. Vizirianakis I.S. (2002) “Pharmaceutical education in the wake of genomic technologies for drug development and personalized medicine”, European Journal of Pharmaceutical Sciences, vol. 15, n. 3, 243-250.